{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-018907","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2025-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.182202+00:00","generated_at":"2026-05-17T02:50:26.048208+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"Telomir-1 reduces DNA methylation of CASP8 and GSTP1 in aggressive prostate cancer model","bullets":["Telomir-1 decreased DNA methylation of CASP8 (apoptosis) and GSTP1 (detoxification) genes at Day 21, vs vehicle and chemo.","Combination of Telomir-1 and chemo showed lower methylation than chemo alone, suggesting potentiation of epigenetic effects.","Rapamycin showed initial methylation reduction at Day 10 but rebounded by Day 21; Telomir-1 showed sustained progressive decrease.","Data derived from mice bearing human aggressive prostate tumors; preclinical, not yet in humans."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-018907","json":"https://secwatch.observer/filing/0001493152-25-018907.json","markdown":"https://secwatch.observer/filing/0001493152-25-018907.md","text":"https://secwatch.observer/filing/0001493152-25-018907.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315225018907/0001493152-25-018907-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315225018907/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:50:26.048208+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}